|
Gene: WDR26 |
Gene summary for WDR26 |
Gene summary. |
Gene information | Species | Human | Gene symbol | WDR26 | Gene ID | 80232 |
Gene name | WD repeat domain 26 | |
Gene Alias | CDW2 | |
Cytomap | 1q42.11-q42.12 | |
Gene Type | protein-coding | GO ID | GO:0000151 | UniProtAcc | Q9H7D7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80232 | WDR26 | CCI_1 | Human | Cervix | CC | 1.63e-02 | 1.02e+00 | 0.528 |
80232 | WDR26 | CCI_2 | Human | Cervix | CC | 5.61e-03 | 7.44e-01 | 0.5249 |
80232 | WDR26 | CCI_3 | Human | Cervix | CC | 1.60e-08 | 7.07e-01 | 0.516 |
80232 | WDR26 | NAFLD1 | Human | Liver | NAFLD | 4.41e-04 | 4.62e-01 | -0.04 |
80232 | WDR26 | S43 | Human | Liver | Cirrhotic | 2.72e-04 | -1.16e-01 | -0.0187 |
80232 | WDR26 | HCC1_Meng | Human | Liver | HCC | 1.64e-59 | 1.07e-02 | 0.0246 |
80232 | WDR26 | HCC2_Meng | Human | Liver | HCC | 1.26e-21 | 2.27e-02 | 0.0107 |
80232 | WDR26 | HCC1 | Human | Liver | HCC | 4.21e-07 | 3.97e+00 | 0.5336 |
80232 | WDR26 | HCC2 | Human | Liver | HCC | 7.04e-09 | 3.24e+00 | 0.5341 |
80232 | WDR26 | Pt13.b | Human | Liver | HCC | 4.37e-09 | 5.69e-02 | 0.0251 |
80232 | WDR26 | S016 | Human | Liver | HCC | 7.90e-04 | 4.11e-01 | 0.2243 |
80232 | WDR26 | S028 | Human | Liver | HCC | 8.23e-12 | 7.86e-01 | 0.2503 |
80232 | WDR26 | S029 | Human | Liver | HCC | 1.78e-10 | 8.74e-01 | 0.2581 |
80232 | WDR26 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.48e-04 | 3.97e-01 | 0.3371 |
80232 | WDR26 | RNA-P17T-P17T-4 | Human | Lung | IAC | 8.11e-04 | 3.21e-01 | 0.343 |
80232 | WDR26 | RNA-P17T-P17T-6 | Human | Lung | IAC | 2.76e-09 | 6.82e-01 | 0.3385 |
80232 | WDR26 | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.52e-04 | 4.63e-01 | 0.3329 |
80232 | WDR26 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.11e-07 | 3.90e-01 | -0.2116 |
80232 | WDR26 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.51e-03 | 5.60e-01 | -0.1941 |
80232 | WDR26 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.73e-04 | 1.99e-01 | -0.0166 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR26 | SNV | Missense_Mutation | rs773725140 | c.1873A>G | p.Ile625Val | p.I625V | Q9H7D7 | protein_coding | tolerated(0.5) | benign(0.007) | TCGA-AC-A3W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
WDR26 | SNV | Missense_Mutation | novel | c.1267G>C | p.Asp423His | p.D423H | Q9H7D7 | protein_coding | deleterious(0) | benign(0.232) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR26 | SNV | Missense_Mutation | c.850G>T | p.Asp284Tyr | p.D284Y | Q9H7D7 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
WDR26 | SNV | Missense_Mutation | novel | c.1430N>C | p.Gly477Ala | p.G477A | Q9H7D7 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
WDR26 | SNV | Missense_Mutation | novel | c.1747G>A | p.Glu583Lys | p.E583K | Q9H7D7 | protein_coding | deleterious(0.01) | possibly_damaging(0.771) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
WDR26 | SNV | Missense_Mutation | c.751C>A | p.His251Asn | p.H251N | Q9H7D7 | protein_coding | deleterious(0.03) | possibly_damaging(0.496) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
WDR26 | SNV | Missense_Mutation | novel | c.373N>A | p.Glu125Lys | p.E125K | Q9H7D7 | protein_coding | tolerated(0.12) | benign(0.04) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
WDR26 | SNV | Missense_Mutation | rs772952060 | c.746N>A | p.Arg249His | p.R249H | Q9H7D7 | protein_coding | deleterious(0.04) | benign(0.246) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
WDR26 | SNV | Missense_Mutation | novel | c.1202N>T | p.Ala401Val | p.A401V | Q9H7D7 | protein_coding | tolerated(0.13) | possibly_damaging(0.61) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR26 | SNV | Missense_Mutation | c.1027N>A | p.Phe343Ile | p.F343I | Q9H7D7 | protein_coding | tolerated(0.15) | benign(0.135) | TCGA-AA-3930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |